VIE •
Healthcare •
Biotechnology •
Quote as of 09/17/2026 17:32
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeVIE
Market Capitalization1,326.16 mln
Float164 mln
Earnings Date11/06/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-4.41
Highly reliable
Relative Strength
82
/ 100
Strongly outperforming
Pre-Tax Margin
-59%
Severely loss-making
Altman Z-Score
-5.77
Deeply distressed
ROA
-21.76
Deeply negative
Business Description
Founded in 1987 and based in Gaithersburg, Maryland, Novavax works to protect people from dangerous infectious diseases by creating and selling vaccines worldwide. Its two main products are a COVID-19 vaccine called Nuvaxovid and a malaria vaccine known as R21 Matrix-M. The company partners with major pharmaceutical firms, including Sanofi, Pfizer, Takeda, and Serum Life Sciences, to produce and distribute its COVID-19 vaccine across global markets.
